has not yet been established whether genetic predictors of multiple sclerosis (MS) susceptibility also influence disease severity and accumulation of disability. Our aim was to evaluate associations between 16 previously validated genetic susceptibility markers and MS phenotype. Patients with clinically isolated syndrome verified by positive magnetic resonance imaging (MRI) and cerebrospinal fluid findings (n ¼ 179) were treated with interferon-b. Disability and volumetric MRI parameters were evaluated regularly for 2 years. Sixteen single-nucleotide polymorphisms (SNPs) previously validated as predictors of MS susceptibility in our cohort and their combined weighted genetic risk score (wGRS) were tested for associations with clinical (conversion to MS, relapses and disability) and MRI disease outcomes (whole brain, grey matter and white matter volumes, corpus callosum cross-sectional area, brain parenchymal fraction, T2 and T1 lesion volumes) 2 years from disease onset using mixed-effect models. We have found no associations between the tested SNPs and the clinical or MRI outcomes. Neither the combined wGRS predicted MS activity and progression over 2-year follow-up period. Power analyses confirmed 90% power to identify clinically relevant changes in all outcome variables. We conclude that the most important MS susceptibility loci do not determine MS phenotype and disease outcomes.
INTRODUCTION
Genetic risk factors have been recognised as important determinants of susceptibility to multiple sclerosis (MS). In particular, the HLA-DRB1*1501 allele was identified repeatedly as the most significant of the genetic susceptibility factors 1 and its causal role in the pathogenesis of MS was suggested. 2 A number of other loci associated with MS susceptibility have been reported. 3 A metaanalysis of genome-wide data from three large patient cohorts identified 16 single-nucleotide polymorphisms (SNPs) as MS susceptibility markers. 4 These SNPs were integrated into a complex score, the weighted genetic risk score (wGRS), whose purpose was to provide a clinical instrument to estimate individual genetic risk of MS. 5 Despite the proven prediction of MS susceptibility, the relationship between these 16 loci (and the derived wGRS) with MS activity and severity has not been established. While some studies suggested that MS severity is not governed by genetic susceptibility factors, [6] [7] [8] other works reported association between the HLA DRB1*1501 polymorphism and MS phenotype. 9, 10 The aim of our current work was to study effects of the 16 validated susceptibility SNPs on MS phenotype. We have used 2-year clinical and volumetric magnetic resonance imaging (MRI) data from 182 patients with clinically isolated syndrome (CIS) confirmed by positive MRI and cerebrospinal fluid findings to examine potential associations of early disease activity with these 16 susceptibility loci and with their integrated wGRS. The cohort used in this study, had previously been used to validate the susceptibility SNPs in the original wGRS study. 5 
RESULTS
We have analysed information from 179 patients from the SET study (Study of Early Interferon b1-a Treatment in High Risk Subjects after CIS) with complete genetic, clinical and volumetric MRI data. Baseline demographic, clinical and MRI characteristics are shown in Table 1 . HLA DRB1*1501 was found in 86 patients (48%), with 5 patients (3%) being homozygous. Sixty-eight (38%) patients presented with a relapse during the 2-year follow-up period and thus converted to clinically definite MS. Average changes of the clinical and MRI parameters over 2 years were as follows: Expanded Disability Status Scale (EDSS) 0 ( À 0.5 to 0.5), Multiple Sclerosis Functional Composite (MSFC) þ 0.5±0.6, brain parenchymal fraction (BPF) À 0.5±0.8%, brain volume À 1.2 ± 1.3%, grey matter volume À 1.9 ± 3.6%, white matter volume À 0.9 ± 3.0%, corpus callosum cross-sectional area À 2.3±3.7%, T2 lesion volume þ 0.1 cm 3 ( À 0.2 to 0.75), T1 lesion volume þ 0.05 cm 3 ( À 0.05 to 0.2) (shown as mean±s.d. or median (interquartile range)).
Of the examined 16 SNPs (see Table 2 ), which were previously replicated as MS susceptibility markers in this cohort, 4 none showed significant associations with accumulation of disability quantified with EDSS and MSFC (PX0.2, mixed-effect models) or progression to clinically definite MS (P40.7, Cox regression). Similarly, none of the SNPs was associated with MRI markers of global and regional brain atrophy: relative changes in whole brain volume, grey matter volume, white matter volume, corpus callosum area and BPF (P40.2, mixed-effect models). Neither did any of the SNPs show any significant associations with T2 or T1 lesion volumes (P40.4, mixed-effect models).
Distribution of the wGRS, which estimates relative cumulative MS susceptibility in individual patients and is based on the 16 examined SNPs, is shown in Figure 1 . Similar to the individual SNPs, the wGRS did not predict any of the outcome measures, that is, change in EDSS or MSFC, number of relapses, time to next relapse, whole brain, grey matter and white matter volume changes, corpus callosum area change, BPF or T2 and T1 lesion volumes (P40.2, mixed-effect or Cox models). Figure 2 shows distributions of the outcome variables by the wGRS.
The power to detect the smallest clinically significant differences in any of the outcome measures contained within the statistical models used in our study exceeded 90%. For the full list of the smallest detectable effect sizes see Table 3 .
DISCUSSION
We have shown that 16 SNPs previously identified as genetic predictors of susceptibility to MS do not predict disease activity and severity early after the initial demyelinating clinical event.
Neither the investigated clinical outcomes (disability, incidence of relapses) nor volumetric MRI markers of disease severity (global and segmented brain atrophy and hyperintense T2 or hypointense T1 lesions) are significantly influenced by any of the examined SNPs or the score estimating their combined effect on MS susceptibility-the wGRS.
The fact that the SNPs tested here predict the susceptibility to MS was demonstrated before, 3, 11, 12 including validation within the cohort used in our present study. 5 The most prominent of these susceptibility loci, HLA DRB1, was shown to be associated with earlier onset of MS in several studies. 9, [13] [14] [15] [16] [17] On the other hand, these studies did not find any effect of HLA DRB1 on MS phenotype and severity of its course. 8, [13] [14] [15] [16] 18 Similarly, other seven SNPs identified as predictive of MS susceptibility in genome-wide association studies (GWAS) were not found to significantly influence severity of physical, psychological or MRI abnormalities in 1006 well characterised MS patients. 6 In addition, a study examining effects of 10 non-HLA susceptibility SNPs, which partially overlapped with our present selection of SNPs, found no association with time to established disability milestones (EDSS steps 4, 6 and 8). 19 Finally, a GWAS in a cohort of 1470 MS patients identified several candidate SNPs with suggested associations with MS disability (none of these fulfilling genomewide significance criteria), of which none was a known MS susceptibility factor. 8 In contrast, other works reported associations between HLA DRB1*1501 and its associated DR2 serotype with disease phenotype. Both were more prevalent among patients with earlier conversion to clinically definite MS, greater T2 lesion volume, more pronounced pathology of normal-appearing white matter, accelerated decrease in brain volume, more rapid accumulation of physical disability and impaired cognition. 9, 10, 20, 21 Apart from the HLA DRB1, a number of other loci were identified to be modestly associated with MS phenotype in a GWAS. 7 However, these loci did not overlap with those related to MS susceptibility. Based on these observations and also on the results of our current study, it is possible to speculate that a certain dichotomy exists between the genes associated with MS susceptibility and the genes associated with MS phenotype, that 
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is, that the risk of disease onset and the severity of its progression are governed by different genetic mechanisms.
We may speculate that while onset of MS is a dichotomy defined by the presence or absence of inflammation, further propagation of the CNS damage may be a continuum driven by inflammation-initiated neurodegeneration. 22 In keeping with this hypothesis, the genes involved in known neurodegenerative disorders may contribute to the progression of MS but not to its onset. For example, an allele in the phosphoenolpyruvate carboxykinase 1 locus (rs8192708 G ), which is associated with cognitive decline in Alzheimer's disease 23 and is not recognised as MS susceptibility factor, 3 was found to be predictive of more pronounced brain atrophy in MS. 24 The extent of the progressive damage in MS may be determined by genes defining antigenic and structural properties of CNS structures, and thus their resistance to destructive processes such as autoimmunity.
The most important limitation of our current study was the relatively small number of tested SNPs. Our present cohort had previously been used to replicate outcomes of a GWAS examining MS susceptibility loci. 4, 5 In this procedure, only the 16 SNPs identified as significant outcomes of the GWAS were genotyped. Furthermore, our analysis did not involve any control group (that is, untreated CIS patients); therefore, we were not able to evaluate interactions between early treatment and the target SNPs. It was previously shown in CIS that treatment with interferon b is effective in reducing conversion to clinically definite MS and in ameliorating brain atrophy. 25 This could diminish the potential influence of genetic factors on the outcome variables. However, our analysis has demonstrated 90% power to identify differences that were smaller than any clinically meaningful changes in the clinical and MRI outcomes, even after their reduction with early treatment. It should be noted that in a number of patients, amelioration of baseline disability was observed during the 2-year follow-up period, as suggested by EDSS and MSFC (see Figure 2) . This was most probably caused by recovery from a recent initial demyelinating event. The recovery may have introduced additional variance in the disability metrics, thus impacting negatively on the power contained within the applied statistical models. Finally, it is worth noting that our cohort represents a population of patients with a very likely diagnosis of MS, as all have shown MRI and cerebrospinal fluid findings that were in keeping with the diagnosis of MS.
We conclude that while the known genetic MS susceptibility factors may help estimate individual risk of MS, they do not contribute to the prediction of disease progression in early MS.
PATIENTS AND METHODS

Study participants
Patients from the SET study (n ¼ 220, registered by EudraCT, 2005-001281-13) were recruited from eight MS centres within the Czech Republic (General University Hospital, Motol University Hospital and Kralovske Vinohrady University Hospital in Praha; KZ Hospital in Teplice; University Hospitals in Brno, Plzen and Olomouc; St. Anne's University Hospital in Brno) between years 2005 and 2009. The SET study was approved by local medical ethics committees and written informed consent was obtained from all subjects. Inclusion criteria were as follows: 18-55 years of age, enrolment within 4 months of first demyelinating clinical event, EDSS p3.5, presence of X2 hyperintense T2 lesions prior to steroid treatment and X2 oligoclonal bands in cerebrospinal fluid. Exclusion criteria were: second relapse before enrolment or any major disease or pregnancy. Genetic material had been obtained from all 182 patients recruited before 2008 for the wGRS validation. 5 The database was locked for analysis in August 2011. Three subjects with incomplete data were excluded and 179 subjects were retained in the final analysis.
Study design
SET is an ongoing investigator-initiated, multicentre, prospective, observational study investigating clinical and MRI predictors of response to interferon b-1a therapy in CIS. 26 After the screening clinical examination, diagnostic MRI and lumbar puncture, patients were treated with methylprednisolone 3-5 g IV (Solu-Medrol; Pfizer, Praha, Czech Republic). Baseline MRI was performed at least 30 days later. Within 4 months of the initial episode, patients' disability was scored using EDSS and MSFC and they commenced treatment with interferon b-1a (Avonex 30 mg IM weekly; Biogen Idec, Weston, MA, USA). Thereafter, the patients were followed in 3-month intervals, with disability rated at months 6, 12, 18 and 24 and MRI scan done at months 6, 12 and 24. EDSS scores were evaluated by accredited raters and MSFC was administered by trained research assistants at each of the participating centres.
A hundred and forty-one (79%) patients remained on the assigned treatment throughout the 2-year follow-up, whereas 22 switched to other interferon preparation (Rebif 44 mg SC TIW; Merck Serono, Geneva, Switzerland), 5 switched to glatiramer acetate (Copaxone 20 mg SC daily; Teva Pharmaceuticals, Petach Tikva, Israel) and 11 discontinued disease modifying therapy. In addition to the disease modifying therapy, 11 patients received add-on azathioprine (Azaprine 50 mg PO BD; Teva Pharmaceuticals), 27 1 patient received mitoxantrone (Refador 10 mg; Teva Pharmaceuticals) with 1 g of methylprednisolone IV monthly over 3 months and 5 patients received oral prednisolone (Prednison 5-10 mg PO daily; Zentiva, Praha, Czech Republic) or methylprednisolone (Medrol 8 mg PO daily; Pfizer). These adjustments were made in accordance with the SET study protocol, in patients showing lack of treatment effect (that is, two moderate relapses or 6-month sustained progression of one EDSS step during 12 months on treatment) or tolerance (unacceptable flu-like symptoms despite symptomatic treatment or threefold increase in liver enzyme concentrations).
Image acquisition and analysis All brain MR images were obtained on one 1.5 T scanner (Gyroscan, Philips Medical Systems, Best, The Netherlands) following a standard protocol. 28 Axial brain images were acquired using fast fluid-attenuated inversion recovery (time to repetition/time to echo/time to inversion: 11000/140/2600 ms, matrix size 256 Â 181, flip angle 901, slice thickness 1.5/0 mm, field of view ¼ 256 mm) and T1-weighted three-dimensional fast field echo images (time to repetition/time to echo: 25/5 ms, flip angle ¼ 301, matrix size 256 Â 256, slice thickness ¼ 1/0 mm, field of view ¼ 256 mm).
Automated image analysis was performed with ScanView.CZ software (www.scanview.cz, designed by JK). 26, 29 After standard image processing, signal intensity was normalised (peak ¼ 10 000, white matter ¼ 5000 artificial units). Overall volume of T2 lesions was measured in homogenised and filtered fast fluid-attenuated inversion recovery images as the area exceeding the intensity of 140% of the white matter and the size of 11 voxels. Overall volume of T1 lesions was measured in T1-weighted images within the areas corresponding to T2 lesions as the area with o82% of the white matter intensity. Non-normalised brain volume was measured in T1-weighted images thresholded at above 4000 artificial units. BPF was calculated as the ratio of the brain volume to the total volume contained within the brain surface contour. Non-normalised grey and white matter volumes were measured in T1-weighted images segmented with SIENAX image segmentation tool, version 2.60 (http:// www.fmrib.ox.ac.uk/analysis/research/siena). 30 Lesion inpainting procedures were not used; the resulting error did not exceed 0.14 ± 0.18% for the grey matter and 0.15 ± 0.20% for the white matter volumetry. Atrophy of the corpus callosum was evaluated as a change in its cross-sectional area, which was measured and averaged in seven three-dimensional reconstructions of T1-weighted sagittal slices per patient (thickness ¼ 1/ 0 mm) using an automated procedure. 29 For the whole brain, grey and white matter volumes and the corpus callosum area, percentage changes relative to the baseline measurements in each patient were used in all analyses. The re-test and inter-rater errors did not exceed 0.5% and 0.3%, respectively.
Genotyping procedures
Genotype data were acquired as part of the previous study, using Sequenom MASS array platform and its iPLEX format following a protocol described elsewhere. 4 The 16 genotyped SNPs were chosen at the end of the replication stage of the previous meta-analysis of genetic susceptibility factors (see Table 2 ): nine of these SNPs exceeded genome-wide significance (Po5 Â 10 À 8 ) and seven SNPs were strongly suggestive of association with MS susceptibility (Po10 À 4 ). 4 Association of all these 16 SNPs with MS susceptibility was further validated in other studies. 3, 11, 12 The combined association of these 16 loci with MS susceptibility was estimated using the wGRS as described before. 5 The wGRS was based on the odds ratios calculated for each of the SNPs from the data from the replication arm of the previous meta-analysis. 4 For each patient, the wGRS was calculated as the sum of the risk allele numbers for each of the 16 SNPs multiplied by the respective weight, this being the natural logarithm of the respective odds ratio. 5 
Statistical analysis
Statistical analyses were carried out with R (http://www.R-project.org) and Statistica 10 (Statsoft, Tulsa, OK, USA) software packages. The hypotheses were tested at the 5% two-tailed level of statistical significance after applying the Benjamini-Hochberg correction. T2 and T1 lesion volumes were normalised using logarithmic transformation.
For each outcome variable (EDSS and MSFC and their changes compared to baseline, whole brain, grey matter, whiter matter and corpus callosum atrophy, BPF, T2 and T1 lesion volumes), associations with each of the 16 SNPs, as well as the wGRS were tested with mixed-effect models adjusted for gender, age and changes in treatment, with subject being the random effect. Cumulative risk of clinically definite MS was estimated using Kaplan-Meier method and its associations with the 16 SNPs and the wGRS were tested with Cox proportional hazards models adjusted for gender, age and changes in treatment.
Power analysis was carried out to estimate the smallest effects detectable with 90% power in all of the tested outcome variables. 
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